Martin Steegmaier
Chief Scientific Officer Molecular Partners AG
Martin Steegmaier, Ph.D., is Chief Scientific Officer and Member of the Management Board of Molecular Partners, appointed in 2025. He was previously Chief Scientific Officer of SOTIO Biotech, where he led the development of a broad pipeline of oncology programs. Martin has extensive experience from senior roles at major biotech and pharma companies. These include Head of Research at MorphoSys, focusing on the development of antibody-based therapeutics in immuno-oncology and hematology-oncology, and positions in antibody discovery and engineering and oncology disease areas at Roche and Boehringer Ingelheim.
Seminars
Monday 8th June 2026
A Next-Generation Logic-Gated Switch-DARPin T-cell Engager with CD2 Co-Stimulation for Improved Safety & Efficacy in MSLN & EpCAM Co-Expressing Solid Cancer
9:30 am
- Clinical development of TCEs for solid tumours is often impaired by off-tumour ontarget and cytokine-release syndrome (CRS) triggered toxicities, and limited efficacy due to T-cell exhaustion
- We designed a logic-gated Switch-DARPin TCE (AND-gate) for tumour-localised immune activation targeting MSLN & EpCAM which are highly co-expressed in OC and other solid tumours. In addition, we built CD2 co-engagement into the Switch- DARPin inducing sustained T-cell proliferation and activity
- This approach provides an opportunity for novel cancer treatments through logicgated tumour-directed immune activation with increased efficacy & safety over single TAA-targeting modalities
